Hemoglobin A1C Calculator

Convert your HbA1c percentage to estimated average blood glucose (eAG) in both mg/dL and mmol/L. This calculator uses the validated ADAG study formula and includes risk level classification based on American Diabetes Association guidelines.

What Is Hemoglobin A1C

Hemoglobin A1C, often written as HbA1c or simply A1C, is a blood test that measures the percentage of your hemoglobin proteins that have glucose attached to them. Since red blood cells live for about 120 days, the A1C test gives a weighted average of your blood sugar control over the past 2 to 3 months.

Unlike a single fasting glucose test that shows your blood sugar at one moment, A1C paints a broader picture. It tells you how well your body has been managing glucose over time. This is why A1C is considered one of the most important tests for both diagnosing and monitoring diabetes.

The test is straightforward. A healthcare provider draws a small blood sample, and the lab measures what percentage of hemoglobin is glycated (coated with sugar). A higher percentage means higher average blood sugar levels. The result is reported as a percentage, such as 5.4% or 7.2%.

For people without diabetes, A1C typically falls between 4% and 5.6%. Values between 5.7% and 6.4% indicate prediabetes, a condition where blood sugar is improved but has not yet reached the threshold for a diabetes diagnosis. An A1C of 6.5% or higher on two separate tests is used to diagnose type 2 diabetes.

A1C to Average Glucose Calculator

Understanding Your Results

When you enter your A1C value into the calculator above, you get back an estimated average glucose (eAG) number. This number represents the average blood glucose concentration over the lifespan of your red blood cells, typically 2 to 3 months.

The result appears in two units. The first is milligrams per deciliter (mg/dL), which is the standard unit in the United States. The second is millimoles per liter (mmol/L), the standard in most other countries and in scientific literature. Both numbers describe the same glucose concentration, just in different measurement systems.

The risk classification below the result tells you where your A1C falls on the clinical spectrum. A green "Normal" label means your A1C is below 5.7%, which is the healthy range. A yellow "Prediabetes" label means you fall between 5.7% and 6.4%, signaling that your blood sugar management needs attention. A red "Diabetes" label appears for values at 6.5% or above.

Keep in mind that this calculator provides estimates based on population averages. Individual variation exists. Two people with the same A1C could have different day-to-day glucose patterns. One person might have relatively stable glucose, while another experiences frequent highs and lows that average out to the same A1C.

A1C to Average Glucose Reference Chart

The table below shows the relationship between common A1C values and their corresponding estimated average glucose levels. This is the same conversion used by the ADA on lab reports.

The ADAG Study Formula

The formula used in this calculator comes from the A1C-Derived Average Glucose (ADAG) study, which was published in 2008 in the journal Diabetes Care. The study enrolled 507 participants, including people with type 1 diabetes, type 2 diabetes, and no diabetes, across 10 international centers.

The researchers collected continuous glucose monitoring data and frequent fingerstick readings over 3 months, then compared those readings to lab A1C values. The resulting formula is:

This formula replaced an older, less precise conversion that had been in use for years. The ADAG formula has a strong linear correlation (r = 0.92) between A1C and average glucose, and it is now the standard used by the ADA and many labs worldwide.

To convert from mg/dL to mmol/L, you divide by 18.015 (the molecular weight of glucose divided by 10). The formula above for mmol/L is simply the mg/dL formula divided by 18.015.

Step-by-step example

For an A1C of 7.0%:

• eAG (mg/dL) = 28.7 x 7.0 - 46.7 = 200.9 - 46.7 = 154.2 mg/dL
• eAG (mmol/L) = 154.2 / 18.015 = 8.6 mmol/L

This means a person with an A1C of 7.0% had an average blood glucose of approximately 154 mg/dL over the preceding 2 to 3 months.

Risk Level Ranges

The American Diabetes Association defines three key ranges for A1C values. Understanding where you fall helps guide treatment decisions and lifestyle changes.

Normal (below 5.7%)

An A1C under 5.7% indicates that blood glucose regulation is working well. Average glucose at this level is below approximately 117 mg/dL (6.5 mmol/L). No diabetes-specific interventions are needed, though maintaining a healthy lifestyle remains important for prevention.

Prediabetes (5.7% to 6.4%)

This range signals impaired glucose metabolism. The body is not processing blood sugar as effectively as it should. Estimated average glucose falls between approximately 117 and 137 mg/dL (6.5 to 7.6 mmol/L). Without intervention, roughly 15% to 30% of people with prediabetes will develop type 2 diabetes within 5 years.

The good news is that prediabetes is reversible. Studies like the Diabetes Prevention Program showed that modest weight loss (5-7% of body weight) and regular physical activity (150 minutes per week) can reduce diabetes risk by 58%.

Diabetes (6.5% and above)

An A1C at or above 6.5% on two separate tests indicates diabetes. Average glucose at 6.5% A1C is approximately 140 mg/dL (7.8 mmol/L). Higher A1C values correspond to progressively higher average glucose and increased risk for complications including retinopathy, nephropathy, neuropathy, and cardiovascular disease.

ADA Guidelines for A1C Management

The American Diabetes Association publishes annually updated Standards of Care that provide evidence-based guidance on A1C targets and management strategies. Here are the key recommendations.

Target A1C for most adults with diabetes

The ADA recommends an A1C target below 7.0% for most nonpregnant adults with diabetes. This target balances the benefits of tight glucose control against the risks of hypoglycemia and treatment burden. Achieving this target has been shown to reduce microvascular complications (eye, kidney, and nerve damage).

Individualized targets

Not everyone should aim for the same number. The ADA recognizes that targets should be personalized:

• Younger adults or those with short-duration diabetes may benefit from tighter control (A1C below 6.5%) if it can be achieved without significant hypoglycemia.
• Older adults, those with a long history of diabetes, or people with limited life expectancy may have less stringent targets (A1C below 8.0%).
• Pregnant individuals with preexisting diabetes should target an A1C below 6.0% if possible without excessive hypoglycemia, ideally below 6.5%.

Monitoring frequency

A1C should be measured at least twice a year for patients who are meeting their glycemic targets. For patients whose therapy has recently changed or who are not meeting goals, quarterly testing (every 3 months) is appropriate.

Factors That Can Affect A1C Accuracy

While A1C is a dependable marker for most people, several conditions can cause it to read higher or lower than your true average glucose. Being aware of these factors helps you and your doctor interpret results correctly.

Conditions that may raise A1C falsely

• Iron deficiency anemia - Lower iron levels can increase the proportion of glycated hemoglobin, pushing A1C higher than the true average glucose.
• Kidney disease - Chronic kidney disease can increase A1C through altered red blood cell lifespan and other mechanisms.
• High triglycerides - Very high triglyceride levels may interfere with some A1C assays.
• Splenectomy - Removal of the spleen can extend red blood cell lifespan, allowing more glycation time.

Conditions that may lower A1C falsely

• Hemolytic anemias - Conditions that destroy red blood cells faster than normal reduce glycation time, lowering A1C.
• Sickle cell disease and other hemoglobinopathies - These can interfere with certain A1C assay methods.
• Recent blood loss or transfusion - Fresh red blood cells have had less time to become glycated.
• Erythropoietin therapy - Stimulating new red blood cell production can lower A1C.
• Pregnancy (second and third trimester) - Increased red blood cell production and turnover can reduce A1C.

Glucose Log Tracker

Use this simple log to track your daily glucose readings. You can record your fasting, pre-meal, and post-meal glucose values to compare with your A1C-derived average glucose. This log is stored only in your browser and can be cleared at any time.

A1C vs Fasting Blood Glucose

Both A1C and fasting blood glucose (FBG) are used to screen for and diagnose diabetes, but they measure different things and have different strengths.

The ADA accepts either test for diagnosis, though they may sometimes give discordant results. If one test indicates diabetes but the other does not, the test that exceeds the diagnostic threshold should be repeated. If the repeat test also exceeds the threshold, diagnosis is confirmed.

How to Improve Your A1C

If your A1C is higher than your target, evidence-based strategies can help bring it down. The following approaches have been shown to meaningfully reduce A1C levels.

Dietary changes

Reducing carbohydrate intake, especially refined carbohydrates and added sugars, is one of the most effective dietary strategies. Research shows that low-carbohydrate diets can reduce A1C by 0.5% to 1.0% over 3 to 6 months. Focusing on whole grains, vegetables, lean proteins, and healthy fats provides sustained energy without sharp glucose spikes.

Physical activity

Both aerobic exercise (walking, cycling, swimming) and resistance training (weight lifting) improve insulin sensitivity and lower blood glucose. The ADA recommends at least 150 minutes of moderate-intensity aerobic activity per week, spread over at least 3 days, with no more than 2 consecutive days without exercise. Adding 2 to 3 sessions of resistance training per week provides additional benefit.

Weight management

For people who are overweight, losing even 5% to 7% of body weight can significantly improve A1C. The Diabetes Prevention Program demonstrated that lifestyle intervention was more effective than medication (metformin) at reducing diabetes risk.

Medication adherence

If your doctor has prescribed diabetes medication, taking it consistently as directed is important. Skipping doses or stopping medication can cause A1C to rise. If side effects are a problem, talk to your healthcare provider about alternatives rather than stopping on your own.

Stress management and sleep

Chronic stress raises cortisol levels, which increases blood glucose. Poor sleep (fewer than 6 hours per night) is associated with higher A1C. Addressing both stress and sleep can contribute to better glucose control.

When and How Often to Test A1C

The frequency of A1C testing depends on your diabetes status and how well your glucose is controlled.

• No diabetes: The ADA recommends screening starting at age 35, or earlier if you have risk factors (overweight, family history, history of gestational diabetes, certain ethnicities). Screening every 3 years is reasonable for low-risk individuals.
• Prediabetes: Annual testing is recommended to monitor for progression to diabetes.
• Diabetes, meeting targets: At least twice a year.
• Diabetes, not meeting targets or therapy changed: Every 3 months (quarterly).

Point-of-care A1C testing, which gives results within minutes during an office visit, is available and can be useful for making real-time treatment adjustments. Lab-based A1C tests are generally more precise and remain the standard for diagnosis.

Limitations of the A1C Test

While A1C is a valuable tool, it is not . Understanding its limitations helps you use it wisely.

First, A1C reflects an average. Two people with the same A1C could have very different glucose patterns. One might have stable glucose near 150 mg/dL all day, while the other swings between 50 and 250 mg/dL. The average is the same, but the second pattern is far more dangerous. Continuous glucose monitoring (CGM) provides additional context that A1C alone cannot.

Second, A1C is weighted toward more recent glucose levels. Because older red blood cells are naturally dying off and being replaced, the most recent 30 days contribute more to the A1C result than the first 30 days of the measurement period. This means a sudden improvement or worsening of glucose control will partially show up in A1C sooner than the "3-month average" label suggests.

Third, as discussed in the factors section above, hemoglobin variants and conditions that alter red blood cell lifespan can skew A1C results. In populations with high prevalence of hemoglobinopathies, alternative markers like fructosamine or glycated albumin may be more appropriate.

Related Health and Fitness Tools

These free tools may also be useful for managing your health.

References and External Resources

The information in this tool is based on the following authoritative sources:

• American Diabetes Association - Understanding A1C - The ADA provides patient-facing information on A1C testing, targets, and management.
• CDC - All About Your A1C - The Centers for Disease Control and Prevention explains A1C testing and what results mean.
• NIDDK - The A1C Test and Diabetes - The National Institute of Diabetes and Digestive and Kidney Diseases offers detailed information on A1C testing methodology and clinical use.
• Wikipedia - Glycated Hemoglobin - General overview of hemoglobin A1C biochemistry and history.

Browser Compatibility

Diabetes Complications and A1C

Research has established a clear link between A1C levels and the risk of diabetes complications. The landmark Diabetes Control and Complications Trial (DCCT) for type 1 diabetes and the United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes both demonstrated that lower A1C levels significantly reduce complication rates.

For every 1% reduction in A1C, the risk of microvascular complications (retinopathy, nephropathy, neuropathy) decreases by approximately 37%. Even modest improvements matter. Reducing A1C from 9% to 8% provides substantial benefit, even if the target of 7% has not yet been reached.

Eye disease (diabetic retinopathy)

Diabetic retinopathy is the leading cause of new blindness in adults. High blood glucose damages the tiny blood vessels in the retina, causing them to leak or become blocked. The DCCT showed that intensive glucose control (A1C around 7%) reduced the risk of developing retinopathy by 76% compared to conventional treatment (A1C around 9%). Annual dilated eye exams are recommended for all people with diabetes.

Kidney disease (diabetic nephropathy)

Diabetes is the leading cause of kidney failure in the United States. Persistent high blood glucose damages the filtering units of the kidneys (glomeruli), eventually leading to protein leaking into the urine and declining kidney function. The DCCT found that intensive glucose control reduced the risk of developing microalbuminuria (early kidney damage) by 39%. Regular testing of urine albumin and blood creatinine can detect kidney disease early when treatment is most effective.

Nerve damage (diabetic neuropathy)

About half of all people with diabetes develop some form of neuropathy. The most common type is peripheral neuropathy, which causes pain, tingling, or numbness in the feet and hands. Over time, loss of sensation can lead to injuries and infections that may result in amputation. The DCCT showed a 60% reduction in neuropathy risk with intensive glucose management. Keeping A1C below 7% is one of the best ways to prevent or slow nerve damage.

Cardiovascular disease

People with diabetes have 2 to 4 times higher risk of heart disease and stroke compared to people without diabetes. While the relationship between A1C and cardiovascular disease is less straightforward than with microvascular complications, maintaining good glucose control is still beneficial. The UKPDS follow-up study showed that early intensive glucose control produced lasting cardiovascular benefits even years after the study ended, a phenomenon called the "legacy effect."

A1C During Pregnancy

A1C testing takes on special importance during pregnancy. For women with preexisting diabetes (type 1 or type 2), the ADA recommends achieving an A1C below 6.5% before conception, or as close to normal as possible without excessive hypoglycemia. During pregnancy, the target is typically below 6.0%.

Gestational diabetes (diabetes that develops during pregnancy) affects about 6% to 9% of pregnancies. Women are typically screened between 24 and 28 weeks of gestation using an oral glucose tolerance test. A1C is not the primary screening tool for gestational diabetes because pregnancy-related changes in red blood cell turnover can make A1C less dependable.

After delivery, women who had gestational diabetes should be retested 4 to 12 weeks postpartum using a fasting glucose or oral glucose tolerance test. They have a significantly higher risk of developing type 2 diabetes later in life. Approximately 50% of women with gestational diabetes develop type 2 diabetes within 5 to 10 years. Postpartum lifestyle changes and regular screening can help delay or prevent this progression.

For women with preexisting diabetes who are planning pregnancy, optimizing A1C before conception is critical. High glucose levels during the first trimester (when organs are forming) significantly increase the risk of birth defects. An A1C above 10% at conception is associated with congenital anomaly rates as high as 20-25%, compared to 2-3% in the general population.

Continuous Glucose Monitoring and A1C

Continuous glucose monitoring (CGM) devices have changed how people with diabetes track their glucose. A CGM provides real-time glucose readings every 1 to 5 minutes using a small sensor inserted under the skin, typically on the arm or abdomen. This gives a much more detailed picture than occasional fingerstick tests.

CGM data produces a metric called "time in range" (TIR), which measures the percentage of time glucose stays between 70 and 180 mg/dL. Research has shown that TIR correlates strongly with A1C. Roughly, each 10% increase in time in range corresponds to about a 0.5% decrease in A1C.

Another CGM metric, the Glucose Management Indicator (GMI), is calculated from the average glucose measured by the CGM. GMI and A1C often track closely, but they can differ. If your GMI is significantly different from your lab A1C, it may indicate that one of the conditions affecting A1C accuracy (discussed earlier) is present.

The key advantage of CGM over A1C is that it reveals glucose variability. Two people with the same A1C of 7% could have very different CGM profiles. One might have stable glucose near 150 mg/dL with 80% time in range. The other might swing from 50 to 350 mg/dL with only 40% time in range. CGM makes these differences visible in a way that A1C cannot.

Medications That Affect Blood Glucose and A1C

Many medications for diabetes work by lowering blood glucose through different mechanisms, which ultimately reduces A1C.

Metformin

Metformin is the most commonly prescribed first-line medication for type 2 diabetes. It works primarily by reducing glucose production in the liver and improving insulin sensitivity. Metformin typically lowers A1C by 1% to 1.5%. It does not cause hypoglycemia when used alone and may help with modest weight loss.

Sulfonylureas

Sulfonylureas (glipizide, glyburide, glimepiride) stimulate the pancreas to release more insulin. They typically lower A1C by 1% to 2% but can cause hypoglycemia and weight gain. They are older medications that remain widely used due to their effectiveness and low cost.

GLP-1 receptor agonists

These injectable medications (semaglutide, liraglutide, dulaglutide) mimic the GLP-1 hormone that helps regulate blood sugar after meals. They lower A1C by 0.5% to 1.8% depending on the specific drug and dose. They also promote weight loss and have been shown to reduce cardiovascular events in some patients.

SGLT2 inhibitors

SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) work by causing the kidneys to excrete more glucose in the urine. They lower A1C by 0.5% to 1.0% and have shown benefits for heart failure and kidney disease. Side effects include urinary tract infections and an increased risk of genital yeast infections.

Insulin

Insulin is the most glucose-lowering medication and is required for all people with type 1 diabetes. For type 2 diabetes, insulin is often added when other medications cannot achieve the A1C target. Insulin can lower A1C by any amount needed but carries the risk of hypoglycemia and weight gain. Modern insulin analogs and insulin pump technology have made dosing more precise and adaptable.

History of A1C Testing

The connection between hemoglobin and glucose was first discovered in the late 1960s. In 1968, researchers Samuel Rahbar and colleagues identified an unusual hemoglobin fraction in patients with diabetes. They published their findings showing that this glycated hemoglobin was present in significantly higher concentrations in people with diabetes compared to healthy individuals.

Through the 1970s, researchers developed laboratory methods to measure HbA1c and investigated its potential as a clinical marker for long-term glucose control. The first clinical assays became available in the early 1980s. These early tests had significant variability between laboratories, making it difficult to compare results from different facilities.

The National Glycohemoglobin Standardization Program (NGSP) was established in 1996 to standardize A1C testing across laboratories. This standardization was critical because the landmark DCCT and UKPDS trials used specific A1C assay methods, and clinical recommendations needed to be based on comparable measurements. Today, most A1C tests are traceable to the DCCT reference, ensuring consistent results worldwide.

In 2010, the American Diabetes Association officially endorsed A1C as a diagnostic test for diabetes, not just a monitoring tool. This was a significant change, as previously only fasting glucose and oral glucose tolerance tests were accepted for diagnosis. The A1C threshold of 6.5% for diagnosis was based on the relationship between A1C and the risk of developing diabetic retinopathy.

More recently, the International Federation of Clinical Chemistry (IFCC) introduced a new reference method that reports A1C in mmol/mol rather than as a percentage. While the percentage format remains standard in the United States, many countries now report A1C in both formats. The conversion between the two is: IFCC (mmol/mol) = (NGSP % - 2.15) x 10.929.

A1C and Ethnic Differences

Research has shown that A1C levels can vary among different racial and ethnic groups even when blood glucose levels are similar. Several studies have found that Black Americans tend to have A1C values approximately 0.4% higher than white Americans with the same average glucose. Similar differences have been observed in Hispanic, Asian, and Native American populations.

The reasons for these differences are not fully understood. Proposed explanations include genetic variations in hemoglobin glycation rates, differences in red blood cell lifespan, and variations in the relationship between glucose and glycated hemoglobin. Some hemoglobin variants that are more common in certain ethnic groups can affect A1C measurement accuracy.

These differences have clinical implications. Using the same A1C thresholds for diagnosis across all populations may lead to underdiagnosis in some groups and overdiagnosis in others. Some researchers have proposed race-specific diagnostic thresholds, while others argue that individual glucose monitoring provides a better assessment than relying solely on A1C.

The ADA currently uses the same A1C thresholds for all populations but acknowledges these differences in its guidelines. Clinicians are encouraged to consider the full clinical picture, including fasting glucose, oral glucose tolerance tests, and continuous glucose monitoring data, when A1C results seem inconsistent with other measures of glucose control.

A1C in Children and Adolescents

A1C management in children with diabetes presents unique challenges compared to adults. Children's bodies are growing and changing, their nutritional needs differ, and the psychological impact of diabetes management on a child must be considered.

The ADA recommends an A1C target below 7% for most children and adolescents with type 1 diabetes, the same as for adults. However, individualization is especially important in pediatrics. Very young children (under 6 years) may have less stringent targets because of their higher risk of hypoglycemia and the difficulty of recognizing low blood sugar symptoms.

Adolescence often brings challenges to A1C control. Hormonal changes during puberty increase insulin resistance, making glucose management harder. The psychological demands of managing a chronic disease during a period of identity formation can lead to diabetes burnout and poor adherence. A1C values often rise during adolescence even in previously well-controlled patients.

Type 2 diabetes in children has been increasing, driven by rising rates of childhood obesity. The ADA recommends screening children who are overweight with additional risk factors starting at age 10 or at the onset of puberty. A1C is used for both diagnosis and monitoring in pediatric type 2 diabetes, with the same thresholds as in adults.

Diabetes Prevention Strategies

Preventing diabetes is far more effective than treating it. For the roughly 96 million American adults with prediabetes, targeted lifestyle interventions can dramatically reduce the risk of progression to type 2 diabetes.

The Diabetes Prevention Program

The Diabetes Prevention Program (DPP) was a landmark clinical trial that enrolled over 3,000 participants with prediabetes across 27 centers. The study compared three groups: intensive lifestyle intervention, metformin therapy, and placebo. The lifestyle group aimed for 7% weight loss and 150 minutes of physical activity per week.

The results were remarkable. The lifestyle intervention reduced diabetes risk by 58% compared to placebo. Among participants over age 60, the reduction was 71%. Metformin reduced risk by 31%. The DPP demonstrated that type 2 diabetes is not inevitable even for people with prediabetes, and that lifestyle changes are more effective than medication for prevention.

Follow-up studies (DPP Outcomes Study) showed that the benefits of the lifestyle intervention persisted for at least 15 years. Participants who successfully maintained weight loss continued to have lower rates of diabetes progression. The initial investment in lifestyle change continued to pay dividends long after the formal program ended.

Weight loss targets

The DPP demonstrated that even modest weight loss produces significant results. A loss of 5-7% of body weight (10-14 pounds for a 200-pound person) was sufficient to substantially reduce diabetes risk. Participants did not reach a "normal" BMI. The key was losing some weight and keeping it off, not achieving a body composition.

Physical activity

The 150 minutes per week target in the DPP is consistent with general exercise guidelines from major health organizations. This amounts to about 30 minutes per day, five days per week, of moderate-intensity activity like brisk walking. The activity does not be performed all at once and can be accumulated in shorter bouts throughout the day.

Exercise improves insulin sensitivity independently of weight loss. Even without losing weight, regular physical activity helps the body process glucose more effectively. This is why exercise is recommended for everyone with prediabetes, regardless of whether weight loss is achieved.

Global Diabetes Statistics

Diabetes has become a global health crisis. According to the International Diabetes Federation, approximately 537 million adults worldwide had diabetes in 2021, and this number is projected to reach 783 million by 2045. The condition is no longer limited to wealthy nations. Low- and middle-income countries now bear the majority of the global diabetes burden.

In the United States alone, 37.3 million people have diabetes (about 11.3% of the population), and an additional 96 million adults have prediabetes. The annual cost of diagnosed diabetes in the US exceeds $327 billion, including direct medical costs and reduced productivity. People with diabetes incur medical expenses approximately 2.3 times higher than those without diabetes.

Type 2 diabetes accounts for 90-95% of all diabetes cases. The primary risk factors are obesity, physical inactivity, family history, age (risk increases after 45), and certain ethnic backgrounds. The rising global prevalence is directly linked to increasing rates of obesity and sedentary lifestyles, particularly in countries undergoing rapid urbanization and dietary transitions.

Type 1 diabetes, which is an autoimmune condition, accounts for approximately 5-10% of diabetes cases. It typically develops in children and young adults and cannot be prevented with lifestyle changes. People with type 1 diabetes require insulin therapy for life. The incidence of type 1 diabetes is increasing globally, with rates rising about 3-5% per year, though the reasons for this increase are not fully understood.

Continuous Glucose Monitor Technology

Continuous glucose monitors (CGMs) have transformed diabetes management over the past decade. Current CGM devices use a tiny sensor filament inserted just beneath the skin that measures glucose in interstitial fluid every 1 to 5 minutes. The sensor transmits data wirelessly to a receiver, smartphone app, or insulin pump.

First-generation CGMs required frequent calibration with fingerstick glucose readings. Modern factory-calibrated CGMs (like the Dexterity G7 and Abbott FreeStyle Libre 3) require no fingerstick calibrations, making them simpler to use. Sensor accuracy has improved dramatically, with mean absolute relative difference (MARD) values below 9% for current devices, approaching the accuracy of fingerstick meters.

CGM data reveals patterns that fingerstick testing cannot capture. Users can see how specific foods, exercise, stress, and sleep affect their glucose in real time. The data can identify dawn phenomenon (early morning glucose rises), post-meal spikes, and nocturnal hypoglycemia that fingerstick testing would miss entirely.

The key CGM metric that complements A1C is time in range (TIR), defined as the percentage of time glucose stays between 70 and 180 mg/dL. An international consensus recommends targeting TIR above 70% for most adults with diabetes, which roughly corresponds to an A1C below 7%. Each 5% increase in TIR is associated with meaningful clinical benefit.

CGM also provides glucose variability metrics, including standard deviation and coefficient of variation. A coefficient of variation below 36% indicates stable glucose with minimal peaks and valleys. High variability, even with a reasonable A1C, is associated with increased risk of hypoglycemia and may contribute independently to diabetes complications.

Alternative Glucose Markers

When A1C testing is unreliable due to hemoglobin variants or altered red blood cell lifespan, healthcare providers may use alternative markers to assess long-term glucose control.

Fructosamine measures glycated albumin and other serum proteins. Because albumin has a half-life of about 2-3 weeks, fructosamine reflects average glucose over the previous 2-3 weeks rather than 2-3 months. This makes it useful for monitoring glucose control over shorter periods, such as after starting a new medication or during pregnancy.

Glycated albumin (GA) is a more specific measure that only looks at the percentage of albumin that is glycated. GA has a reference range of approximately 11-16% for people without diabetes. It is not affected by hemoglobin variants and is gaining adoption as a complement to A1C in populations where A1C may be unreliable.

1,5-anhydroglucitol (1,5-AG) is a naturally occurring sugar that competes with glucose for reabsorption in the kidneys. When blood glucose is high, less 1,5-AG is reabsorbed, so serum levels drop. Low 1,5-AG levels indicate recent hyperglycemic episodes, making it a marker of glucose variability rather than average glucose. It is particularly useful for detecting postprandial (after-meal) glucose spikes that A1C may miss.

Point-of-Care A1C Testing

Point-of-care (POC) A1C testing allows healthcare providers to measure A1C during an office visit and get results within minutes rather than waiting days for lab results. This enables same-visit treatment decisions. POC devices use a small fingerstick blood sample and immunoassay or boronate affinity methods to determine the A1C percentage. The NGSP certifies specific POC devices for accuracy. While POC testing is convenient, lab-based tests remain the gold standard for diagnosis because of their higher precision. POC testing is best suited for monitoring known diabetes patients during routine visits.

Frequently Asked Questions

What is HbA1c and what does it measure?

HbA1c (hemoglobin A1c) measures the percentage of hemoglobin proteins in your blood that are coated with sugar (glycated). It reflects your average blood sugar levels over the previous 2 to 3 months, giving a longer-term picture than a single glucose reading.

What is the ADAG formula for converting A1C to average glucose?

The ADAG formula is: eAG (mg/dL) = 28.7 x A1C - 46.7. To convert to mmol/L, divide the mg/dL result by 18.015. This formula was established by the ADAG study published in 2008 in Diabetes Care.

What is a normal A1C level?

According to the American Diabetes Association, a normal A1C is below 5.7%. Prediabetes is diagnosed at 5.7% to 6.4%. An A1C of 6.5% or higher on two separate tests indicates diabetes.

How often should I get my A1C tested?

The ADA recommends A1C testing at least twice a year for people with diabetes who are meeting treatment goals, and quarterly for those whose therapy has changed or who are not meeting glycemic goals. People without diabetes may be tested as part of routine screening starting at age 35.

Can factors other than blood sugar affect A1C results?

Yes. Conditions that affect red blood cell turnover can alter A1C results. These include iron deficiency anemia, sickle cell disease, thalassemia, kidney disease, liver disease, blood transfusions, and certain medications. Pregnancy can also affect A1C accuracy.

What is estimated average glucose (eAG)?

Estimated average glucose (eAG) is the translation of your A1C percentage into the same units (mg/dL or mmol/L) that you see on your glucose meter. It gives you a practical number to compare your lab A1C with your daily glucose readings.

Is A1C the same as fasting blood sugar?

No. Fasting blood sugar is a single-point measurement taken after at least 8 hours without food. A1C reflects the average blood sugar over 2-3 months. Both tests are used to diagnose and monitor diabetes, but they measure different things.

What A1C target should people with diabetes aim for?

The ADA generally recommends an A1C target below 7% for most adults with diabetes. However, targets may vary based on individual factors like age, duration of diabetes, other health conditions, and risk of hypoglycemia. Your healthcare provider will set a personalized goal.

Last updated: March 19, 2026

Last verified working: March 23, 2026 by Michael Lip